EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Brii Biosciences's enterprise value is HK$-2,062.73 Mil.
Brii Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.68 Mil. Therefore, Brii Biosciences's EV-to-Revenue for today is -3,055.90.
The historical rank and industry rank for Brii Biosciences's EV-to-Revenue or its related term are showing as below:
HKSE:02137'
s EV-to-Revenue Range Over the Past 10 Years
Min: -3400.28 Med: -23.52 Max: 110.63
Current: -3055.9
During the past 5 years, the highest EV-to-Revenue of Brii Biosciences was 110.63. The lowest was -3400.28. And the median was -23.52.
HKSE:02137's EV-to-Revenue is ranked better than 99.9% of 1034
companies
in the Biotechnology industry
Industry Median: 7.69
vs HKSE:02137: -3055.90
As of today (2024-06-23), Brii Biosciences's stock price is HK$1.09.
Brii Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.00. Therefore, Brii Biosciences's PS Ratio for today is 1,090.00.
Brii Biosciences EV-to-Revenue Historical Data
The historical data trend for Brii Biosciences's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Brii Biosciences's EV-to-Revenue
For the Biotechnology subindustry, Brii Biosciences's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Brii Biosciences's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Brii Biosciences's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Brii Biosciences's EV-to-Revenue falls into.
Brii Biosciences's current Enterprise Value is HK$-2,062.73 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Brii Biosciences's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.68 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brii Biosciences's share price for today is HK$1.09.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was HK$0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Brii Biosciences EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Brii Biosciences's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Brii Biosciences (HKSE:02137) Business Description
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed towards developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as the CNS diseases, which have public health burdens in China and worldwide. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02137 has been successfully added to your 